Complementary and Alternative Therapies for Cancer

Oncologist

Volumn 9, Issue 1, 2004, Pages 80-89

  Cassileth, Barrie R ^a   Deng, Gary ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Alternative medicine; Cancer; Complementary therapies; Dietary supplements; Herbs

Indexed keywords

AE 941; ANTINEOPLASTIC AGENT; ANTIOXIDANT; AYURVEDIC DRUG; CAMPTOTHECIN; ESSIAC; FLOR ESSENCE; HERBACEOUS AGENT; HOMEOPATHIC AGENT; INDIRUBIN; KRESTIN; NATURAL PRODUCT; NON PRESCRIPTION DRUG; PACLITAXEL; PC SPES; PHENYLACETIC ACID; PLANT EXTRACT; UNCLASSIFIED DRUG; VINCRISTINE; VISCUM ALBUM EXTRACT; VITAMIN;

ACUPUNCTURE; ALTERNATIVE MEDICINE; BIOENERGY; BIOLOGICAL THERAPY; CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CHINESE MEDICINE; CLINICAL PRACTICE; CLINICAL TRIAL; DIET SUPPLEMENTATION; ESTROGEN ACTIVITY; GARLIC; GINGER; GINKGO BILOBA; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HYPNOSIS; IMMUNOAUGMENTATION THERAPY; MACROBIOTIC DIET; MASSAGE; MULTIMODALITY CANCER THERAPY; MUSIC THERAPY; PHYTOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAXATION TRAINING; REVIEW; SERUM; SHARK; SIDE EFFECT; TANACETUM PARTHENIUM; TRADITIONAL MEDICINE; VITAMIN INTAKE;

COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; HUMANS; INFORMATION SERVICES; NEOPLASMS; PHYTOTHERAPY; VITAMINS;

EID: 1642579678     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-1-80     Document Type: Review

References (129)

1. Weiger WA, Smith M, Boon H et al. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 2002;137:889-903.
2. Adams J, Sibbritt DW, Easthope G et al. The profile of women who consult alternative health practitioners in Australia. Med J Aust 2003;179:297-300.
3. Chrystal K, Allan S, Forgeson G et al. The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. NZ Med J 2003;116:U296.
4. Lee MM, Chang JS, Jacobs B et al. Complementary and alternative medicine use among men with prostate cancer in 4 ethnic populations. Am J Public Health 2002;92:1606-1609.
5. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-1575.
6. Complementary and alternative medicines in cancer therapy. Publication BFHC0462. http://www.datamonitor.com/all/reports/product_summary.asp?pid=BFHC0462, accessed 12/19/2003.
7. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-782.
8. Ni H, Simile C, Hardy AM. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 2002;40:353-358.
9. Burstein HJ, Gelber S, Guadagnoli E et al. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340:1733-1739.
10. Ganz PA, Desmond KA, Leedham B et al. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39-49.
11. Vickers AJ, Cassileth BR. Unconventional therapies for cancer and cancer-related symptoms. Lancet Oncol 2001;2:226-232.
12. Cooper RA, Henderson T, Dietrich CL. Roles of nonphysician clinicians as autonomous providers of patient care. JAMA 1998;280:795-802.
13. Cherkin DC, Deyo RA, Sherman KJ et al. Characteristics of visits to licensed acupuncturists, chiropractors, massage therapists, and naturopathic physicians. J Am Board Fam Pract 2002;15:463-472.
14. Smith MJ, Logan AC. Naturopathy. Med Clin North Am 2002;86:173-184.
15. Eisenberg DM, Cohen MH, Hrbek A et al. Credentialing complementary and alternative medical providers. Ann Intern Med 2002;137:965-973.
16. American Chiropractic Association. Chiropractic: state of the art. Arlington, VA: American Chiropractic Association, 1994.
17. Baer HA. The sociopolitical status of U.S. naturopathy at the dawn of the 21st century. Med Anthropol Q 2001;15:329-346.
18. Leake R, Broderick JE. Current licensure for acupuncture in the United States. Altern Ther Health Med 1999;5:94-96.
19. National Certification Commission for Acupuncture and Oriental Medicine. About us. http://www.nccaom.org/aboutus.htm, accessed 09/29/03.
20. National Cancer Institute. Complementary and alternative medicine resources at NCI-designated cancer centers. Survey results. http://cpen.nci.nih.gov/planning_resources/cam_survey_results.htm, accessed 09/29/03.
21. Druss BG, Rosenheck RA. Association between use of unconventional therapies and conventional medical services. JAMA 1999;282:651-656.
22. Institute of Medicine. Exploring complementary and alternative medicine. In: The Richard and Hinda Rosenthal Lectures 2001. Washington, DC: The National Academies Press, 2003:26.
23. Cassileth BR. The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York: W. W. Norton & Company, Inc., 1998:16-52.
24. Zhang JT. New drugs derived from medicinal plants. Therapie 2002;57:137-150.
25. U.S. Food and Drug Administration. Homeopathy: real medicine or empty promises. http://www.fda.gov/fdac/features/096_home.html, accessed 09/29/03.
26. Memorial Sloan-Kettering Cancer Center. Information resource: About herbs, botanicals and other products. http://www.mskcc.org/abuotherbs, accessed 09/29/03.
27. Ernst E. A systematic review of systematic reviews of homeopathy. Br J Clin Pharmacol 2002;54:577-582.
28. Cucherat M, Haugh MC, Gooch M et al. Evidence of clinical efficacy of homeopathy. A meta-analysis of clinical trials. HMRAG. Homeopathic Medicines Research Advisory Group. Eur J Clin Pharmacol 2000;56:27-33.
29. Linde K, Clausius N, Ramirez G et al. Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. Lancet 1997;350:834-843.
30. Green S. A critique of the rationale for cancer treatment with coffee enemas and diet. JAMA 1992;268:3224-3227.
31. Hildenbrand GL, Hildenbrand LC, Bradford K et al. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review. Altern Ther Health Med 1995;1:29-37.
32. Macrobiotic diets for the treatment of cancer. CA Cancer J Clin 1989;39:248-251.
33. Kushi LH, Cunningham JE, Hebert JR et al. The macrobiotic diet in cancer. J Nutr 2001;131(suppl 11):3056S-3064S.
34. Moertel CG, Fleming TR, Creagan ET et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985;312:137-141.
35. Creagan ET, Moertel CG, O'Fallon JR et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979;301:687-690.
36. Rosa L, Rosa E, Sarner L et al. A close look at therapeutic touch. JAMA 1998;279:1005-1010.
37. O'Mathuna DP. Evidence-based practice and reviews of therapeutic touch. J Nurs Scholarsh 2000;32:279-285.
38. Cassileth BR, Vlassov VV, Chapman CC. Health care, medical practice, and medical ethics in Russia today. JAMA 1995;273:1569-1573.
39. Brown CS, Ling FW, Wan JY et al. Efficacy of static magnetic field therapy in chronic pelvic pain: a double-blind pilot study. Am J Obstet Gynecol 2002;187:1581-1587.
40. Segal NA, Toda Y, Huston J et al. Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double-blind clinical trial. Arch Phys Med Rehabil 2001;82:1453-1460.
41. Gironell A, Kulisevsky J, Lorenzo J et al. Transcranial magnetic stimulation of the cerebellum in essential tremor: a controlled study. Arch Neurol 2002;59:413-417.
42. Weinstein S. The anticonvulsant effect of electrical fields. Curr Neurol Neurosci Rep 2001;1:155-161.
43. Pelka RB, Jaenicke C, Gruenwald J. Impulse magnetic-field therapy for migraine and other headaches: a double-blind, placebo-controlled study. Adv Ther 2001;18:101-109.
44. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13(suppl 1):1-11.
45. Buckner JC, Malkin MG, Reed E et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74:137-145.
46. Burzynski SR, Lewy RI, Weaver RA et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4:91-101.
47. Harrison LE, Wojciechowicz DC, Brennan MF et al. Phenyl-acetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery 1998;124:541-550.
48. Tsuda H, Sata M, Kumabe T et al. Quick response of advanced cancer to chemoradiation therapy with antineoplastons. Oncol Rep 1998;5:597-600.
49. Moss R. Cancer Therapy: The Burton Goldberg Group, Alternative Medicine. Puyallup, Washington: Future Medicine Publishing, Inc., 1993:577.
50. Questionable methods of cancer management. Immuno-augmentative therapy (IAT). CA Cancer J Clin 1991;41:357-364.
51. Dupont E, Falardeau P, Mousa SA et al. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 2002;19:145-153.
52. Miller DR, Anderson GT, Stark JJ et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998;16:3649-3655.
53. Batist G, Patenaude F, Champagne P et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002;13:1259-1263.
54. Falardeau P, Champagne P, Poyet P et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001;28:620-625.
55. Unproven methods of cancer management. Laetrile. CA Cancer J Clin 1991;41:187-192.
56. Moertel CG, Fleming TR, Rubin J et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 1982;306:201-206.
57. Pierce JP, Faerber S, Wright FA et al. A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials 2002;23:728-756.
58. Rock CL. Antioxidant supplement use in cancer survivors and the general population. In: Free Radicals: The Pros and Cons of Antioxidants. NIH: Bethesda, MD 2003.
59. Cassileth BR, Lucarelli CD. Herb-Drug Interactions in Oncology. Hamilton, Canada: B. C. Decker, 2003:1-467.
60. Slifman NR, Obermeyer WR, Aloi BK et al. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med 1998;339:806-811.
61. Drew AK, Myers SP. Safety issues in herbal medicine: implications for the health professions. Med J Aust 1997;166:538-541.
62. Cheng B, Hung CT, Chiu W. Herbal medicine and anaesthesia. Hong Kong Med J 2002;8:123-130.
63. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology (Huntingt) 1999;13:1003-1008; discussion 1008, 1011-1002.
64. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001;61:2163-2175.
65. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355:134-138.
66. Tamayo C, Richardson MA, Diamond S et al. The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res 2000;14:1-14.
67. Kienle GS, Berrino F, Bussing A et al. Mistletoe in cancer-a systematic review on controlled clinical trials. Eur J Med Res 2003;8:109-119.
68. Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 2003;107:262-267.
69. Niimoto M, Hattori T, Tamada R et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 1988;18:681-686.
70. Nakazato H, Koike A, Saji S et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994;343:1122-1126.
71. Ogoshi K, Satou H, Isono K et al. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 1995;18:216-222.
72. Torisu M, Hayashi Y, Ishimitsu T et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990;31:261-268.
73. Mitomi T, Tsuchiya S, Iijima N et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 1992;35:123-130.
74. Toi M, Hattori T, Akagi M et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer 1992;70:2475-2483.
75. Morimoto T, Ogawa M, Orita K et al. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur J Cancer 1996;32A:235-242.
76. Iino Y, Yokoe T, Maemura M et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995;15:2907-2911.
77. Yokoe T, Iino Y, Takei H et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res 1997;17:2815-2818.
78. Small EJ, Frohlich MW, Bok R et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18:3595-3603.
79. de la Taille A, Buttyan R, Hayek O et al. Herbal therapy PCSPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000;164:1229-1234.
80. Oh WK, George DJ, Hackmann K et al. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001;57:122-126.
81. de la Taille A, Hayek OR, Buttyan R et al. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 1999;84:845-850.
82. Pfeifer BL, Pirani JF, Hamann SR et al. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000;85:481-485.
83. Sovak M, Seligson AL, Konas M et al. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst 2002;94:1275-1281.
84. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. JAMA 1996;276:313-318.
85. Sellick SM, Zaza C. Critical review of 5 nonpharmacologic strategies for managing cancer pain. Cancer Prev Control 1998;2:7-14.
86. Bindemann S, Soukop M, Kaye SB. Randomised controlled study of relaxation training. Eur J Cancer 1991;27:170-174.
87. Bridge LR, Benson P, Pietroni PC et al. Relaxation and imagery in the treatment of breast cancer. BMJ 1988;297:1169-1172.
88. Walker LG, Walker MB, Ogston K et al. Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer 1999;80:262-268.
89. Vasterling J, Jenkins RA, Tope DM et al. Cognitive distraction and relaxation training for the control of side effects due to cancer chemotherapy. J Behav Med 1993;16:65-80.
90. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982;307:1476-1480.
91. Arakawa S. Use of relaxation to reduce side effects of chemotherapy in Japanese patients. Cancer Nurs 1995;18:60-66.
92. Smith M, Casey L, Johnson D et al. Music as a therapeutic intervention for anxiety in patients receiving radiation therapy. Oncol Nurs Forum 2001;28:855-862.
93. Wang SM, Kulkarni L, Dolev J et al. Music and preoperative anxiety: a randomized, controlled study. Anesth Analg 2002;94:1489-1494.
94. Kaempf G, Amodei ME. The effect of music on anxiety. A research study. AORN J 1989;50:112-118.
95. Kwekkeboom KL. Music versus distraction for procedural pain and anxiety in patients with cancer. Oncol Nurs Forum 2003;30:433-440.
96. Haun M, Mainous RO, Looney SW. Effect of music on anxiety of women awaiting breast biopsy. Behav Med 2001;27:127-132.
97. Hanser SB, Thompson LW. Effects of a music therapy strategy on depressed older adults. J Gerontol 1994;49:P265-P269.
98. Burns DS. The effect of the bonny method of guided imagery and music on the mood and life quality of cancer patients. J Music Ther 2001;38:51-65.
99. Waldon EG. The effects of group music therapy on mood states and cohesiveness in adult oncology patients. J Music Ther 2001;38:212-238.
100. Zimmerman L, Pozehl B, Duncan K et al. Effects of music in patients who had chronic cancer pain. West J Nurs Res 1989;11:298-309.
101. Beck SL. The therapeutic use of music for cancer-related pain. Oncol Nurs Forum 1991;18:1327-1337.
102. Field T, Morrow C, Valdeon C et al. Massage reduces anxiety in child and adolescent psychiatric patients. J Am Acad Child Adolesc Psychiatry 1992;31:125-131.
103. Fraser J, Kerr JR. Psychophysiological effects of back massage on elderly institutionalized patients. J Adv Nurs 1993;18:238-245.
104. Ahles TA, Tope DM, Pinkson B et al. Massage therapy for patients undergoing autologous bone marrow transplantation. J Pain Symptom Manage 1999;18:157-163.
105. Grealish L, Lomasney A, Whiteman B. Foot massage. A nursing intervention to modify the distressing symptoms of pain and nausea in patients hospitalized with cancer. Cancer Nurs 2000;23:237-243.
106. Kaptchuk TJ. Acupuncture: theory, efficacy, and practice. Ann Intern Med 2002;136:374-383.
107. Han JS. Acupuncture: neuropeptide release produced by electrical stimulation of different frequencies. Trends Neurosci 2003;26:17-22.
108. Shen J. Research on the neurophysiological mechanisms of acupuncture: review of selected studies and methodological issues. J Altern Complement Med 2001;7(suppl 1):S121-S127.
109. Foster JM, Sweeney BP. The mechanisms of acupuncture analgesia. Br J Hosp Med 1987;38:308-312.
110. Shen J, Wenger N, Glaspy J et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial. JAMA 2000;284:2755-2761.
111. Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999;88:1362-1369.
112. Vickers AJ. Can acupuncture have specific effects on health? A systematic review of acupuncture antiemesis trials. J R Soc Med 1996;89:303-311.
113. Alimi D, Rubino C, Leandri EP et al. Analgesic effects of auricular acupuncture for cancer pain. J Pain Symptom Manage 2000;19:81-82.
114. Ernst E, Pittler MH. The effectiveness of acupuncture in treating acute dental pain: a systematic review. Br Dent J 1998;184:443-447.
115. Melchart D, Linde K, Fischer P et al. Acupuncture for idiopathic headache. Cochrane Database Syst Rev 2001;1:CD001218.
116. Filshie J, Redman D. Acupuncture and malignant pain problems. Eur J Surg Oncol 1985;11:389-394.
117. Leng G. A year of acupuncture in palliative care. Palliat Med 1999;13:163-164.
118. Dillon M, Lucas C. Auricular stud acupuncture in palliative care patients. Palliat Med 1999;13:253-254.
119. Acupuncture. NIH Consens Statement 1997;15:1-34.
120. Cassileth BR, Schraub S, Robinson E et al. Alternative medicine use worldwide: the International Union Against Cancer survey. Cancer 2001;91:1390-1393.
121. Richardson MA, Sanders T, Palmer JL et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514.
122. Bernstein BJ, Grasso T. Prevalence of complementary and alternative medicine use in cancer patients. Oncology (Huntingt) 2001;15:1267-1272; discussion 1272-1278, 1283.
123. Cassileth BR. Complementary therapies: overview and state of the art. Cancer Nurs 1999;22:85-90.
124. National Institutes of Health, National Center for Complementary and Alternative Medicine. http://nccam.nih.gov, accessed 09/29/03.
125. National Cancer Institute, Office of Cancer Complementary and Alternative Medicine. http://www3.cancer.gov/occam, accessed 09/29/03.
126. American Cancer Society. Making treatment decisions: complementary and alternative therapies. http://www.cancer.org/docroot/ETO/ETO_5.asp?sitearea=ETO, accessed 09/29/03.
127. National Cancer Institute. Complementary and alternative medicine. http://www.cancer.gov/cancerinfo/treatment/cam, accessed 09/29/03.
128. Barrett S. Quackwatch: your guide to health fraud, quackery, and intelligent decisions. http://www.quackwatch.org, accessed 09/29/03.
129. The University of Texas, M.D. Anderson Cancer Center. Complementary/integrative medicine. http://www.mdander son.org/departments/cimer, accessed 09/29/03.